Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Aprea Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
13.4
14.2
21
37.9
23.9
16.4
7.63
9.36
7.04
General and administrative
2.46
2.29
8.59
14.9
13.6
21
8.43
6.46
6.48
Operating expenses
15.9
16.5
29.5
52.8
37.4
113
16.1
15.8
13.5
Operating income
-37.4
-113
-15.5
-14.3
-13.2
Other non-operating income
0.66
0.96
1.48
-0.67
0.32
0.73
1.19
1.36
0.63
Income tax
0
0
0
0
0
0
0
0
0
Net income
-15.2
-15.5
-28.1
-53.5
-37.1
-113
-14.3
-13
-12.6
EBITDA
-37.4
-113
-15.5
-14.3
-13.2
EPS, basic
-252.70
-258.07
-89.61
-48.54
-33.46
-65.21
-3.79
-2.35
-1.93
EPS, diluted
-252.70
-258.07
-89.61
-48.54
-33.46
-65.21
-3.79
-2.35
-1.93
Shares, basic (weighted)
0.06
0.06
0.31
1.1
1.11
1.73
3.77
5.51
6.54
Shares, diluted (weighted)
0.06
0.06
0.31
1.1
1.11
1.73
3.77
5.51
6.54
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
24.4
65.7
130
89
53.1
28.8
21.6
22.8
14.6
Other current assets
0.32
2.96
3.4
3.51
1.37
0.91
0.73
0.96
Total current assets
66
133
92.4
56.6
30.2
22.5
23.6
15.6
Property, plant and equipment
0.02
0.04
0.04
0.02
0
0.09
0.08
0.06
Lease right-of-use assets
0.52
0.32
0.19
Other non-current assets
0
0
0.03
0.03
0.28
0.27
Total assets
66
134
92.8
56.8
30.2
22.7
24
15.9
Accounts payable
1.74
2.18
4.5
1.77
0.84
1.67
1.35
0.71
Accrued liabilities
0.62
0.96
1.52
1.42
1.4
1.02
0.47
0.77
Deferred revenue
0.53
Total current liabilities
4.87
9.06
15.3
7.32
3.2
4.39
3.36
2.76
Lease liabilities
0.3
0.08
Total liabilities
4.87
9.36
15.4
7.32
3.2
5.7
4.67
3.49
Paid-in capital
19.7
226
231
241
330
336
351
357
Retained earnings
-62.5
-90.5
-144
-181
-294
-308
-321
-334
Other comprehensive income
-8.76
-11.5
-10
-10.4
-10.6
-10.6
-10.6
-10.6
Shareholders' equity
-35.8
-51.4
124
77.4
49.5
25.6
17
19.3
12.4
Total equity
-35.8
-51.4
124
77.4
49.5
25.6
17
19.3
12.4
Total liabilities and equity
66
134
92.8
56.8
30.2
22.7
24
15.9
Shares outstanding
0.06
1.1
22.1
1.14
2.77
3.9
5.48
8.19
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-15.2
-15.5
-28.1
-53.5
-37.1
-113
-14.3
-13
-12.6
Depreciation and amortization
0.01
0.01
0.01
0.03
0.01
0
0.01
0.02
0.02
Stock-based compensation
0.4
0.33
1.35
4.98
Change in payables
0.33
0.21
0.44
2.33
-2.73
-0.86
0.83
-0.31
-0.65
Cash from operations
-14
-15.3
-26.7
-41.8
-37.7
-25
-12.2
-13.6
-12.9
Capital expenditures
-0
-0.03
-0.03
-0.09
-0.02
Cash from investing
-0
-0.03
-0.03
-0.09
-0.02
Stock issued
0
0.07
0.15
1.54
0.68
5.79
16.1
5.05
Cash from financing
23.3
56.4
92.6
0.15
1.75
0.68
5.14
14.8
4.64
Exchange rate effect
1.39
0.16
-1.42
0.61
-0
Net change in cash
9.34
41.1
65.8
-41.7
-35.9
-24.3
-7.13
1.25
-8.25
Free cash flow
-15.3
-26.7
-41.8
-12.3
-13.6
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.76 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-32.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-29.1%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-35.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-21.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-30.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-33.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-19.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-29.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
18.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
55.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
42.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
13.6x
Current assets / current liabilities.
Quick ratio
13.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.23
Cash from operations / diluted weighted shares.
Book value per share
$3.10
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.25x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.25x
Market cap / tangible book value, when positive.
Earnings yield
-128.5%
Net income / market cap (the inverse of P/E).
Was Aprea Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $12.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.